Saxagliptin Improved Key Measures of Glucose Control When Added to a Sulphonylurea or Thiazolidinedione in People With I

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995, regarding the research, development and commercialization of products. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among other risks, there can be no guarantee that the product described in this release will receive regulatory approval. There can be no assurance that if approved, the product will be commercially successful. Forward-looking statements in the press release should be evaluated together with the many uncertainties that affect Bristol-Myers Squibb's business, particularly those identified in the cautionary factors discussion in Bristol-Myers Squibb's Annual Report on Form 10-K for the year ended December 31, 2007, its Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. Bristol-Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in research, development, manufacturing and marketing of prescription pharmaceuticals and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of US $29.55 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infection product sales. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index.

    
    ---------------------------------
    (1) American Diabetes Association. All About Diabetes.
    (a) http://www.diabetes.org/about-diabetes.jsp; accessed Aug. 7, 2008
    (b) http://www.diabetes.org/type-2-diabetes.jsp; accessed Aug. 7, 2008
    (2) National Diabetes Information Clearinghouse. National Institute of
        Diabetes and Digestive and Kidney Diseases, National Institutes of
        Health. http://diabetes.niddk.nih.gov; accessed Aug. 7, 2008.
    (a) http://diabetes.niddk.nih.gov/dm/pubs/ov...;
        accessed Aug. 7, 2008
    (b) http://diabetes.niddk.nih.gov/dm/pubs/ov...; Type
        2 Diabetes section; accessed Aug. 7, 2008
    (c) http://diabetes.niddk.nih.gov/dm/pubs/ov...; Type
        2 Diabetes section; accessed Aug. 7, 2008
    (d) http://diabetes.niddk.nih.gov/dm/pubs/ov...; Type
        2 Diabetes section; accessed Aug. 7, 2008
    (3) American Heart Association. Type 2 Diabetes; "Who Is At Risk For Type
        2 Diabetes" section.
        http://www.americanheart.org/presenter.j...;
        accessed Aug. 7, 2008.
    (4) International Diabetes Foundation. Diabetes Atlas. Third Edition.
        2006. Page 22.
    (5) American Diabetes Association, Accord Trial Questions & Answers,
        http://www.diabetes.org/for-media/pr-accord-trail-QA-020608....;
        accessed Aug. 7, 2008
    (6) International Diabetes Federation, Global Guidelines for Type 2
        Diabetes, Chapter 6: Glucose Control Levels, page 27.

http://www.idf.org/webdata/docs/GGT2D%20...; accessed Aug. 18, 2008

    
    (7) American Diabetes Association, A1C Test,
        http://www.diabetes.org/type-1-diabetes/a1c-test.jsp; accessed Aug.
        7, 2008

    Contacts
    Media Investors
    Carmel Hogan                 John Elicker
    Bristol-Myers Squibb         Bristol-Myers Squibb
    Office: +33-1-58-83-65-55    Office: +1-212-546-3775
    Cell: +33-6-74-10-76-58      john.elicker@bms.com
    carmel.hogan@bms.com
    Jim Minnick                  Mina Blair
    AstraZeneca                  AstraZeneca
    Office: +1-302-886-5135      Office: +44-20-7304-5084
    Cell: +1-610-457-1828        mina.blair@astrazeneca.com
    jim.minnick@astrazeneca.com

Contacts: Media Investors, Carmel Hogan, Bristol-Myers Squibb, Office: +33-1-58-83-65-55, Cell: +33-6-74-10-76-58, carmel.hogan@bms.com; John Elicker, Bristol-Myers Squibb, Office: +1-212-546-3775, john.elicker@bms.com; Jim Minnick, AstraZeneca, Office: +1-302-886-5135, Cell: +1-610-457-1828, jim.minnick@astrazeneca.com; Mina Blair, AstraZeneca, Office: +44-20-7304-5084, mina.blair@astrazeneca.com